Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-26
2008-10-14
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07435745
ABSTRACT:
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
REFERENCES:
patent: 2830991 (1958-04-01), Keller et al.
patent: 3560495 (1971-02-01), Frankus
patent: 3563986 (1971-02-01), Frankus
patent: 3625946 (1971-12-01), Heinrich et al.
patent: 3705162 (1972-12-01), Graudums et al.
patent: 4552888 (1985-11-01), Koppel et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5021404 (1991-06-01), Folkman et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5405855 (1995-04-01), Andrulis, Jr.
patent: 5434170 (1995-07-01), Andrulis, Jr.
patent: 5443824 (1995-08-01), Piacquadio
patent: 5502066 (1996-03-01), Heinemann
patent: 5605684 (1997-02-01), Piacquadio
patent: 5605914 (1997-02-01), Muller
patent: 5629327 (1997-05-01), D'Amato
patent: 5643915 (1997-07-01), Andrulis, Jr. et al.
patent: 5654312 (1997-08-01), Andrulis, Jr. et al.
patent: 5679696 (1997-10-01), Fenton et al.
patent: 5731325 (1998-03-01), Andrulis, Jr. et al.
patent: 6235756 (2001-05-01), D'Amato
patent: 1182709 (1970-03-01), None
patent: 0325199 (1989-07-01), None
patent: 0357061 (1990-03-01), None
patent: 58-131978 (1983-08-01), None
patent: 63-119500 (1988-05-01), None
patent: WO 91/10424 (1991-07-01), None
patent: WO 92/14455 (1992-09-01), None
patent: WO 92/18496 (1992-10-01), None
patent: WO 94/20085 (1994-09-01), None
patent: WO 95/04533 (1995-02-01), None
Gutman et al. Failure of Thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Research, 1996, 16:3673-3677.
Thomas et al. Current role of thalidomide in cancer treatment. Current Opinion in Oncology, 2000, 12:564-573.
Alexanian et al. Primary dexamethasone treatment of multiple myeloma. Blood, 1992, vol. 80, No. 4, pp. 887-890.
Hendler, S.S. et., “Immune Modulators Thalidomide”, The Oxygen Breakthrough 30 Days to an Illness-Free Life, William Morrow and Company, Inc., New York, pp. 217-219 (1989).
Kenyon, et al., “The Discovery of New Inhibitors of Angiogenesis Using an Improved Mouse Corneal Neovascularization Model”, Association for Research in Vision and Opthalmology, 1995 Annual Meeting, Fort Lauderdale, Florida, No. 459-367, p. S94 (Abstract Only) (1995).
Neubert, “Teratogenicity: Any Relationship to Carcinogenicity?”, International Agency for Research on Cancer, Cedex, France, Institute for Toxicology and Embryopharmacology, Free University of Berlin, Berlin Federal Rep. of Germany, pp. 169-178, (1979).
Peyron, et al., “The Pharmacological Basis for the Treatment of Phodermatoses”, Biochime, vol. 68, No. 6, pp. 899-904 (1986).
Proenca, N.G., “Thalidomide: An Eclectic Medication in Dermatology”, Rev. Paul. Med., vol. 107, No. 1, pp. 41-46. (Abstract Only) (1989).
Robbins, K.C. “The Plasminogen-Plasmin Enzyme System”, Fibrinolysis, Hemostatsis and Thronbosis Basic Principles and Clinical Practice, 2ndEd., Chapter 21, pp. 340-351 (1987).
Smith, et al., “Studies on the Relationship Between the Chemical Structure and Embryotixic Activity of Thalidomide and Related Compounds”, Chemical Structure and Embryopathy, London, pp. 194-209 (1965).
Wesolowski, et al., “Effect of Light on a Murine Model of Retinopathy of Prematurity”, Assn. for Research in Vision and Ophthalmology, Annual Meeting, Sarasota, Florida (1992).
Algire, G. H., “Vascular Reactions of Normal and Malignant tissues In Vivo. I. Vascular Reactions of Mice to Wounds and to Normal and Neoplastic Transplants”,J. Nat'l Canc. Inst., pp. 73-85 (1945).
Allegri, A., “Confermata l'inefficacia della Talidomide Nella Terapia dei Tumori”,Gazzetta Medica Italiana, pp. 124-127 (1964).
Ambs, S. et al., “Interactive Effects of Nitric Oxide and the p53 Tumor Suppressor Gene in Carcinogenesis and Tumor Progression”,The FASEB Journal, vol. 11, pp. 443-448 (1997).
Apt, W. “Effect of Thalidomide on the Course of Experimental Chagas' Disease”,BOI. Chil. Parasitol, vol. 20, No. 3, pp. 84-86 (1965).
Aronson, et al., “Thalidomide-Induced Peripheral Neuropathy. Effect of Serum Factor on Nerve Cultures”,Arch. Dermatol., vol. 120, No. 11, pp. 1466-1470 (1984).
Bach, et al., “Studies on the Possible Anti-Neoplastic Effect of Thalidomide”,ACTA Pathologica ET Microbiologica scandinavica, vol. 59, pp. 491-499 (1963).
Bach, et al., “Thalidomide in Cancer Chemotherapy”,The Lancet, vol. 1, p. 1271 (1963).
Bahmer, F.A., “Therapie bel lymphozytischer Infiltration”,Der Hautarzt, vol. 43, p. 663 (1992).
Balabanova, et al., “Lupus Erythermatosus Hypertrophicus et Profundus”,Z. Hautkr., vol. 67, No. 9, pp. 812-815 (1992).
Barnes, et al., “Tumor Necrosis Factor Production in Patients with Leprosy”,Infection and Immunity, vol. 60, No. 4, pp. 1441-1446 (1992).
Barnhill, et al., “Thalidomide: Use and Possible Mode of Action in Reactional Lepromatous Leprosy and in Various Other Conditions”,J. Am. Acad. Dermatol., vol. 7, No. 3, pp. 317-323 (1982).
Barnhill, R. et al., “Studies on the Anti-inflammatory Properties of Thalidomide: Effects on Polymorphonuclear Leukocytres and Monocytes”,J. Am. Acad. Derm., vol. 11, No. 5, Part 1, pp. 814-819 (1984).
Barriere, H., “Traitement par la thalidomide”,La Presse Médicale, vol. 12, No. 15, pp. 963 (1983).
Bazzoli, et al., “The Effects of Thalidomide and Two Analogues on the Regenerating Forelimb of the Newt”,J. Embryol. Exp. Morph., vol. 41, pp. 125-135 (1977).
Beck, Jr. et al. “Vascular Development: Cellular and Molecular Regulation”,The FASEB Journal, vol. 11, pp. 365-374 (1997).
Beccerica, E., “L'approccio terapeutico al paziente anziano con artrite reumatoide”,Clin. Ter., vol. 122, pp. 289-298 (1987).
Belaube, P. et al., “Should Thalidomide be Rehabilitated?”,Sem. Hop. Paris, vol. 59, No. 45, pp. 3101-3104 (1983).
Bensinger, W.I., “Supportive Care in Marrow Transplantation”,Curr. Opin. Oncol.,vol. 4, No. 4, pp. 614-623 (1992).
Bernal, et al., “Cellular Immune Effects of Thalidomide in Actinic Prurigo”,Int'l. J. of Dermat., vol. 31, No. 8, pp. 599-600 (1992).
Blair, R. et al., “Human Mast Cells Stimulate Vascular Tube Formation”,Journal of Clinical Investigation, vol. 99, No. 11, pp. 2691-2700 (1997).
Blaschke, V. et al., Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere,Arzneimittel Forsch./Drug Res., vol. 29, No. II, pp. 1640-1642 (1979).
Bonifacino, J. et al., “A Peptide Sequence Confers Retention and Rapid Degradation in the Endoplasmic Reticulum”,Science, vol. 2, pp. 79-80 (1990).
Bonnetblanc, et al., “Thalidomide and Recurrent Aphthous Stomatitis: a Follow-up Study”,Dermatology, vol. 193, No. 4, pp. 321-323 (1996).
Boodman, S.G., “Questions About a Popular Prenatal Test”,The Washington Post(1992).
Bowers, et al., “Effect of Thalidomide on Orogenital Ulceration”,Br. Med. Journ., vol. 287, No. 6395, pp. 799-800 (1983).
Braun, et al., “Thalidomide Metabolite Inhibits Tumor Cell Attachment to Concanavalin a Coated Surfaces”,Biochem. Biophys. Res. Comm., vol. 98, No. 4, pp. 1029-1034 (1981).
Brem, H. et al., “Interstitial Chemotherapy with Drug Polymer Implants for the Treatment of Recurrent Gliomas”,J. Neurosurg., vol. 74, pp.
Anderson James D
Celgene Corporation
Jones Day
Marschel Ardin
LandOfFree
Methods and compositions for inhibition of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibition of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibition of angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002412